PDK4 and non-small cell lung carcinoma: In contrast, three KRAS- or EGFR-driven non-small cell lung cancer (NSCLC) cell lines treated with TGFβ or erlotinib to induce EMT displayed reduced glycolysis to oxidation ratio and lower PDK4 expression [23].